Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

<div>Changes of central foveal thickness from baseline to month 12 in patients with macular edema secondary to branch retinal vein occlusion treated by intravitreal aflibercept or bevacizumab.</div>

Journal of Ophthalmology

fig2

Figure 2

Figure 2: Comparison of the Efficacy of Intravitreal Aflibercept and Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion 